Literature DB >> 12841861

Basilar hyperlucency in a patient with emphysema due to hypocomplementemic urticarial vasculitis syndrome.

Ziad Ghamra1, James K Stoller.   

Abstract

Disproportionate emphysematous involvement of the lung bases, compared with the apices, sometimes called basilar hyperlucency, is an unusual radiographic pattern that has been reported primarily in patients with alpha-1 antitrypsin deficiency, but also in individuals with emphysema caused by intravenous injection of methylphenidate. We present a patient with emphysema associated with hypocomplementemic urticarial vasculitis syndrome and whose chest radiograph demonstrated basilar hyperlucency. To the extent that basilar hyperlucency has not been well recognized as a feature of hypocomplementemic urticarial vasculitis syndrome, this report extends the spectrum of causes of this unusual radiographic pattern of emphysema.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841861

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  4 in total

Review 1.  Pulmonary vasculitis: diagnosis and endovascular therapy.

Authors:  Kiran Batra; Murthy Chamarthy; Rodrigo Caruso Chate; Kirk Jordan; Fernando Uliana Kay
Journal:  Cardiovasc Diagn Ther       Date:  2018-06

2.  Hypocomplementemic urticarial vasculitis syndrome: a case report and literature review.

Authors:  Andrew Buck; Jim Christensen; Morgan McCarty
Journal:  J Clin Aesthet Dermatol       Date:  2012-01

Review 3.  Hypocomplementemic urticarial vasculitis syndrome.

Authors:  Luis J Jara; Carmen Navarro; Gabriela Medina; Olga Vera-Lastra; Miguel A Saavedra
Journal:  Curr Rheumatol Rep       Date:  2009-12       Impact factor: 4.686

4.  Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults.

Authors:  Anna Stainer; Alex Rice; Anand Devaraj; Joseph Luke Barnett; Jacqueline Donovan; Maria Kokosi; Andrew Gordon Nicholson; Tom Cairns; Athol Umfrey Wells; Elisabetta Augusta Renzoni
Journal:  BMC Pulm Med       Date:  2019-10-24       Impact factor: 3.320

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.